Information Provided By: 
Fly News Breaks for April 15, 2019
AGN
Apr 15, 2019 | 08:54 EDT
Jefferies analyst David Steinberg started Allergan with a Hold rating and $155 price target. While the company has a dominant aesthetics business and a leading eyecare franchise, it is facing multiple pending competitors to Botox and $3.5B in loss of exclusivities for several key products, Steinberg tells investors in a research note. Further, following a string of pipeline setbacks, Allergan will be even more challenged to deliver its growth objectives over the coming years, says the analyst.
News For AGN From the Last 2 Days
There are no results for your query AGN
